iShares Neuroscience and Healthcare ETF
Price through Nov 16, 2026 · Flows through Nov 13, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Nov 16, 2026. Holdings snapshot retrieved Nov 16, 2026.
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.
IBRN price
Table
| Date | IBRN close |
|---|---|
| Oct 16, 2026 | $29.97 |
| Oct 19, 2026 | $30.79 |
| Oct 20, 2026 | $31.84 |
| Oct 21, 2026 | $31.51 |
| Oct 22, 2026 | $31.75 |
| Oct 23, 2026 | $31.36 |
| Oct 26, 2026 | $31.60 |
| Oct 27, 2026 | $32.24 |
| Oct 28, 2026 | $32.92 |
| Oct 29, 2026 | $33.29 |
| Oct 30, 2026 | $32.84 |
| Nov 2, 2026 | $32.52 |
| Nov 3, 2026 | $33.26 |
| Nov 4, 2026 | $33.97 |
| Nov 5, 2026 | $32.89 |
| Nov 6, 2026 | $33.83 |
| Nov 9, 2026 | $34.87 |
| Nov 10, 2026 | $34.79 |
| Nov 11, 2026 | $35.41 |
| Nov 12, 2026 | $34.34 |
| Nov 13, 2026 | $34.20 |
| Nov 16, 2026 | $33.47 |
Daily net flows, 1M
Net inflow over the range: +$2M
- Inflow / above zero
- Outflow / below zero
Show as table
| Label | Value ($) |
|---|---|
| Oct 13 | −$80.6K |
| Oct 14 | $0 |
| Oct 15 | −$128.4K |
| Oct 16 | $125.8K |
| Oct 19 | $0 |
| Oct 20 | $0 |
| Oct 21 | $0 |
| Oct 22 | $0 |
| Oct 23 | $0 |
| Oct 26 | $0 |
| Oct 27 | −$125.5K |
| Oct 28 | $128.1K |
| Oct 29 | $0 |
| Oct 30 | $0 |
| Nov 2 | $0 |
| Nov 3 | $0 |
| Nov 4 | $0 |
| Nov 5 | $0 |
| Nov 6 | $0 |
| Nov 9 | $1.7M |
| Nov 10 | $49.5K |
| Nov 11 | −$220.5K |
| Nov 12 | $448K |
| Nov 13 | −$243.6K |
Money keeps arriving — +$2M of net inflows over the past month, about 20.5% of the fund's asset base, while the price has returned +3.6% so far this year. At 0.47% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | BIIBBIOGEN | 5.33% | $251.65 | -0.7% | ||
| 2 | NBIXNEUROCRINE BIOSCIENCES | 5.09% | $165.31 | -1.2% | ||
| 3 | EWTXEDGEWISE THERAPEUTICS | 4.96% | $43.68 | -4.9% | ||
| 4 | ALKSALKERMES | 4.75% | $46.53 | -1.1% | ||
| 5 | ARGXARGENX SE | 4.43% | $950.95 | -0.9% | ||
| 6 | AXGNAXOGEN | 4.28% | $55.38 | -1.0% | ||
| 7 | PTCTPTC THERAPEUTICS | 4.29% | $60.97 | -4.0% | ||
| 8 | PRAXPRAXIS PRECISION MEDICINES | 4.30% | $310.27 | -5.4% | ||
| 9 | DNTHMAGENTA THERAPEUTICS INC | 3.98% | $89.55 | -2.5% | ||
| 10 | SRRKSCHOLAR ROCK HOLDING | 3.65% | $44.54 | +3.1% | ||
| 11 | DYNDYNE THERAPEUTICS | 3.27% | $16.70 | -2.7% | ||
| 12 | ACADACADIA PHARMACEUTICALS | 3.03% | $18.67 | -0.4% | ||
| 13 | XENEXENON PHARMACEUTICALS | 3.21% | $39.26 | -3.0% | ||
| 14 | BHVNBIOHAVEN | 2.67% | $13.80 | -0.1% | ||
| 15 | SRPTSAREPTA THERAPEUTICS | 2.39% | $15.13 | -5.8% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 67Sector weights
- Healthcare100%
- Health Care98.18%
- Information Technology1.08%
- Cash and/or Derivatives0.74%
Show as table
| Item | Value (%) |
|---|---|
| Healthcare | 100% |
| Health Care | 98.18% |
| Information Technology | 1.08% |
| Cash and/or Derivatives | 0.74% |
Country weights
- United States73.61%
- Belgium4.43%
- Korea (South)3.81%
- South Korea3.8%
- Denmark3.45%
- Sweden3.08%
- Australia2.61%
- Japan2.31%
Show as table
| Item | Value (%) |
|---|---|
| United States | 73.61% |
| Belgium | 4.43% |
| Korea (South) | 3.81% |
| South Korea | 3.8% |
| Denmark | 3.45% |
| Sweden | 3.08% |
| Australia | 2.61% |
| Japan | 2.31% |
| 1 week | -3.8% |
| 1 month | +11.7% |
| 3 months | -14.5% |
| 6 months | -3.8% |
| YTD | +3.6% |
| 1 year | — |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | +$33K |
| 1 month | +$2M |
| 3 months | +$2M |
| YTD | +$4M |
| 1 year | +$4M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
Monthly net flows
- Inflow / above zero
- Outflow / below zero
Show as table
| Label | Value ($) |
|---|---|
| Nov | $0 |
| Dec | $0 |
| Jan | $0 |
| Feb | $0 |
| Mar | $0 |
| Apr | $0 |
| May | $0 |
| Jul | $1.7K |
| Aug | $2M |
| Sep | −$59.5K |
| Oct | $10.2K |
| Nov | $1.8M |
The top holding is 5.3% of the book; the top ten carry 45%. Spread across 85+ names, it behaves like roughly 36 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| CAPR CAPRICOR THERAPEUTICS | $906,988 | $3M |
| ARGX ARGENX SE | $2M | $1M |
| NBIX NEUROCRINE BIOSCIENCES | $965,247 | $12,455 |
| BIIB BIOGEN | $587,112 | $372,253 |
| SRPT SAREPTA THERAPEUTICS | $288,925 | $480,042 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IBRN on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.6B | +$917M | -44bp on fee · 4856× the assets · +$917M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -44bp on fee · 2140× the assets · +$199M in over the month | Head-to-head |
| IJH iShares Core S&P Mid-Cap ETF | 0.05% | $123.7B | +$109M | -42bp on fee · 14424× the assets · +$109M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $34B | +$587M | -43bp on fee · 3965× the assets · +$587M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$422M | -43bp on fee · 2768× the assets · +$422M in over the month | Head-to-head |

